Human bronchial-pulmonary proteomics in coronavirus disease 2019 (COVID-19) pandemic: applications and implications. (2nd November 2021)

• Record Type: Journal Article
• Authors: Tan, Heng Wee; Xu, Yan-Ming; Lau, Andy T. Y.
• Is Part Of: Expert review of proteomics. Volume 18:Number 11(2021)
• Page Start: 925
• Page End: 938
• Publication Date: 2021-11-02
• Subjects: SARS-CoV-2 -- COVID-19 -- lung diseases -- multi-omics -- mass spectrometry -- organoids -- microarray -- affinity purification -- proximity labelling; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1080/14789450.2021.2010549
• Languages: English
• ISSNs: 1478-9450

Abstract

ABSTRACT: Introduction: The outbreak of the newly discovered human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has disrupted the normal life of almost every civilization worldwide. Studies have shown that the coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 can affect multiple human organs and physiological systems, but the respiratory system remains the primary location for viral infection. Areas covered: We summarize how omics technologies are used in SARS-CoV-2 research and specifically review the current knowledge of COVID-19 from the aspect of human bronchial-pulmonary proteomics. Also, knowledge gaps in COVID-19 that can be fulfilled by proteomics are discussed. Expert opinion: Overall, human bronchial-pulmonary proteomics plays an important role in revealing the dynamics, functions, tropism, and pathogenicity of SARS-CoV-2, which is crucial for COVID-19 biomarker and therapeutic target discoveries. To more fully understand the impact of COVID-19, research from various angles using multi-omics approaches should also be conducted on the lungs as well as other organs.